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The high prevalence of obesity and diabetes in developed
and developing nations poses a great health challenge [1,
2]. Obesity is one of the major causes of insulin resistance
and type-2 diabetes [3]. Type-1 diabetes is primarily due to
the autoimmune-mediated destruction of pancreatic beta-
cell leading to insulin deficiency [4, 5]. This is generally
accompanied by alterations in lipid metabolism, enhanced
hyperglycemia-mediated inflammation and oxidative stress,
endothelial cell dysfunction, and apoptosis. Similarly, type-2
diabetes is characterized by elevated inflammation, glucotox-
icity, lipotoxicity, and apoptosis that leads to the progressive
loss of beta cells and ultimately to insulin insufficiency
at later stages of the disease [4, 5]. Thus, in diabetes,
inflammation could be triggered by hyperglycemia and/or
immune response. However, elevated inflammatory events
not only may affect insulin production in type-2 and type-
1 diabetes but also may affect insulin response in target
tissues causing insulin resistance [3]. Although insulin resis-
tance has traditionally been associated with type-2 diabetes,
mounting evidence indicates that the incidence of insulin
resistance in type-1 diabetes is increasing. Therefore, novel
mechanistic approaches deciphering the role of inflammation
in insulin resistance in type-1 and type-2 diabetes are needed.
Many pathophysiological agents are implicated in insulin
resistance. Although the exact nature of these factors is not
completely understood, a high consensus of opinion suggests
that inflammation, oxidative stress, and genetic, habitual,
environmental, and epigenetic factors are implicated.
There has been significant advancement in elucidating the
mechanisms implicated in insulin resistance, overt diabetes,
and related cardiometabolic diseases [1–9]. However, novel
mechanistic studies deciphering the role of inflammation in
these chronic diseases are needed. Similarly, novel studies
addressing the effect of inflammation on genetic and epige-
netic factors that lead to insulin resistance, overt diabetes, and
related cardiometabolic complications are needed.Therefore,
this special issue highlights research and review papers that
address a wide spectrum of inflammation-related mecha-
nisms associated with insulin resistance, type-1 diabetes,
type-2 diabetes, and related cardiometabolic complications.
Accordingly, in an article featuring in this special issue, L.
Zhang and coworkers investigated the pathophysiological
role of tribbles homolog-3 (TRB3) in diabetic nephropathy, a
common complication of diabetes. The authors reported that
TRB3 may trigger renal fibrosis by regulating transforming
growth factor 𝛽1 (TGF-𝛽1) and collagen type-IV through
a signaling pathway involving extracellular signal-regulated
kinase and mitogen-activated protein kinase. TGF-𝛽 is a
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glycoprotein and cytokine with diverse roles in many cellular
events including reproduction [10]. On the other hand,
gamma interferon (IFN-𝛾), another cytokine that is tradi-
tionally known for its role in innate and adaptive immunity,
is increasingly reported to play a role in reproduction [11].
In this special issue, D. L. G. Fagundes et al. showed that
IFN-𝛾 and TGF-𝛽 modulate the phagocytic activity in the
colostrum, maternal blood, and cord blood of pregnant
diabetic women.There is an interesting reciprocal interaction
between TGF-𝛽 and macrophage migration inhibitory factor
(MIF) [12]. MIF is a proinflammatory cytokine that promotes
immune cell recruitment following injury and polymorphism
of MIF which has been associated with several diseases
[13, 14]. In a related study by E. Valde´s-Alvarado et al.,
the association of MIF gene polymorphism, a complication
that is commonly associated with obesity, diabetes, and
hypertension, and susceptibility to acute coronary syndrome
was reported in a research article of this special issue.
Furthermore, in a clinical study by N. A. Sinicato and
coworkers, the role of cytokines such as tumor necrosis
factor alpha, interleukin- (IL-) 6, and interleukin- (IL-) 10
in systemic lupus erythematosus, an autoimmune disease
that is associated with a variety of different cardiovascular
complications including atherosclerosis, was reported. Many
cytokines are known to potentiate inflammatory cascades by
modulating macrophage polarization [15]. The role of the
different macrophage M1 and M2 phenotypes in obesity is
becoming increasingly clear [3, 15, 16]. In a related article
featuring in this special issue, K. Fjeldborg et al. have
shed more light on the preponderance of macrophage M2
phenotype that was associated with a parallel reduction of the
macrophage M1 phenotype in obese subjects. Macrophage-
induced inflammation remains an important feature in
insulin resistance and type-2 diabetes; thus, as an alternative
strategy, A. L. Guadarrama-Lo´pez et al. underscored the
beneficial effects of polyunsaturated fatty acids and vitamin
D in diabetes and related complications in a review article
contained in this issue.
Diabetic retinopathy is another complication of diabetes
and is amongst the leading causes of vision impairment [17]
and a significant number of patients with diabetic retinopathy
are also known to be affected by diabetic macular edema
[18]. A common denominator between diabetic retinopathy
and diabetic macular edema is the elevated levels of role of
vascular endothelial growth factor (VEGF) [19, 20]. In this
special issue, a review article by F. R. Stefanini and coworkers
is featured highlighting the role of intravitreal injection of
anti-VEGF as a therapeutic strategy against diabetic macular
edema.
Collectively the articles featuring in this special issue
constitute a cocktail of original research and reviews that
would stimulate further research in this area given the
increasing incidence of diabetes, obesity, hypertension, and
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